Homozygous ⍺-Thalassemia Treated with Intrauterine Transfusions and Unrelated Donor Hematopoietic Cell Transplantation - 08/08/11
Doi : 10.1016/j.jpeds.2008.11.031
Joanna S. Yi, MD a, Christopher L. Moertel, MD b, ⁎ 
, K. Scott Baker, MD b
, K. Scott Baker, MD b a Department of Pediatrics, University of Minnesota, Minneapolis, MN
b Division of Pediatric Hematology/Oncology Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN
Reprint requests: Christopher L. Moertel, MD, Mayo Mail Code 484/420 Delaware St SE, Minneapolis, MN 55455Résumé |
Recently, intrauterine transfusions and hematopoietic cell transplantation (HCT) have changed homozygous alpha-thalassemia from a frequently fatal disease to a potentially survivable condition. We present a patient with Hemoglobin Bart's disease who was cured after failing to engraft with 1 unrelated HCT, but engrafting after a second unrelated donor HCT.
Le texte complet de cet article est disponible en PDF.Abbreviations : ATG, BMT, GVHD, Hb, HCT, HLA, TBI, TLI
Plan
| The authors declare no conflicts of interest. |
© 2009
Mosby, Inc. Tous droits réservés.
Vol 154 - N° 5
P. 766-768 - mai 2009 Retour au numéro
Article précédent
- Orotracheal Tube Insertion in Extremely Low Birth Weight Infants
- Gil Amarilyo, Francis B. Mimouni, Asaf Oren, Semen Tsyrkin, Dror Mandel
- Closing the Loophole: Midwives and the Administration of Vitamin K in Neonates
- Noemi Adame, Shannon L. Carpenter
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?